Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer

被引：0
|
作者：
Kraeber-Bodere, F. [1 ,2 ]
Goldenberg, D. M. [3 ]
Chatal, J. F. [4 ]
Barbet, J. [2 ,4 ]
机构：
[1] Univ Hosp, Dept Nucl Med, Nantes, France
[2] Univ Nantes, INSERM, Canc Res Ctr, Nantes, France
[3] Ctr Mol Med & Immunol, Garden State Canc Ctr, Belleville, NJ USA
[4] Univ Nantes, Arronax Cyclotron, Nantes, France
来源：
CURRENT ONCOLOGY | 2009年 / 16卷 / 05期
关键词：
Pretargeted radioimmunotherapy; medullary thyroid cancer; calcitonin; BISPECIFIC ANTIBODY; PROGNOSTIC-FACTORS; BIVALENT HAPTEN; IMATINIB MESYLATE; FOLLOW-UP; CARCINOMA; SURVIVAL; CHEMOEMBOLIZATION; OPTIMIZATION; CALCITONIN;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：296 / 301
页数：6
相关论文
共 50 条
  • [1] Pretargeted Radioimmunotherapy in Rapidly Progressing, Metastatic, Medullary Thyroid Cancer
    Kraeber-Bodere, Francoise
    Salaun, Pierre-Yves
    Oudoux, Aurore
    Goldenberg, David M.
    Chatal, Jean-Francois
    Barbet, Jacques
    CANCER, 2010, 116 (04) : 1118 - 1125
  • [2] Pretargeted radioimmunotherapy (pRAIT) in medullary thyroid cancer (MTC)
    Kraeber-Bodere, Francoise
    Salaun, Pierre-Yves
    Ansquer, Catherine
    Drui, Delphine
    Mirallie, Eric
    Faivre-Chauvet, Alain
    Barbet, Jacques
    Goldenberg, David M.
    Chatal, Jean-Francois
    TUMOR BIOLOGY, 2012, 33 (03) : 601 - 606
  • [3] Pretargeted radioimmunotherapy (pRAIT) in progressive medullary thyroid cancer (MTC)
    Salaun, Pierre
    Bournaud, Claire
    Bardet, Stephane
    Vuillez, Jean-Philippe
    Taieb, David
    Ansquer, Catherine
    Barbet, Jacques
    Goldenberg, David
    Chatal, Jean-Francois
    Kraeber-Bodere, Francoise
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52
  • [4] Pretargeted radioimmunotherapy (PT-RAIT) in progressive medullary thyroid cancer (MTC)
    Salaun, Pierre
    Oudoux, Aurore
    Bournaud, Claire
    Vuillez, Jean Philippe
    Taieb, David
    Ansquer, Catherine
    Rousseau, Caroline
    Barbet, Jacques
    Goldenberg, David M.
    Kraeber-Bodere, Francoise
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50
  • [5] Pretargeted radioimmunotherapy (PT-RAIT) in progressive medullary thyroid cancer (MTC)
    Salaun, P. Y.
    Oudoux, A.
    Bournaud, C.
    Bardet, S.
    Vuillez, J.
    Taieb, D.
    Ansquer, C.
    Rousseau, C.
    Bridji, B.
    Barbet, J.
    Goldenberg, D. M.
    Chatal, J.
    Kraeber-Bodere, F.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S291 - S291
  • [6] Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft
    Kraeber-Bodéré, F
    Saï-Maurel, C
    Campion, L
    Faivre-Chauvet, A
    Mirallié, E
    Chérel, M
    Supiot, S
    Barbet, J
    Chatal, JF
    Thédrez, P
    MOLECULAR CANCER THERAPEUTICS, 2002, 1 (04) : 267 - 274
  • [7] Pretargeted radioimmunotherapy, a potential cancer treatment
    Lam, L
    Liu, XY
    Cao, Y
    DRUGS OF THE FUTURE, 2003, 28 (02) : 167 - 173
  • [8] Assessment of combined radioimmunotherapy and chemotherapy for treatment of medullary thyroid cancer
    Stein, R
    Juweid, M
    Zhang, CH
    Goldenberg, DM
    CLINICAL CANCER RESEARCH, 1999, 5 (10) : 3199S - 3206S
  • [9] PRETARGETED RADIOIMMUNOTHERAPY OF CANCER
    AXWORTHY, DB
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1995, 210 : 12 - NUCL
  • [10] 18F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma
    Salaun, Pierre-Yves
    Campion, Loic
    Ansquer, Catherine
    Frampas, Eric
    Mathieu, Cedric
    Robin, Philippe
    Bournaud, Claire
    Vuillez, Jean-Philippe
    Taieb, David
    Rousseau, Caroline
    Drui, Delphine
    Mirallie, Eric
    Borson-Chazot, Francoise
    Goldenberg, David M.
    Chatal, Jean-Francois
    Barbet, Jacques
    Kraeber-Bodere, Francoise
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (08) : 1501 - 1510
12345